Fresenius has issued a software release to address issues that could interrupt treatment with its Ivenix large volume pumps.

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. A voluntary safety recall of widely used Alaris infusion ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced a new initiative to address safety problems associated with external infusion pumps and is ...

CHICAGO (Reuters) - U.S. health regulators are placing renewed focus on preventing problems associated with infusion pumps, widely used devices that deliver fluids, such as medication and nutrients, ...

An unspecified number of ambulatory infusion pumps were recalled because of nearly 3,700 complaints related to several product issues, the FDA said March 20. InfuTronix voluntarily recalled five types ...

Hospira ($HSP) now faces a Class I recall--the FDA's most serious--because of malfunctioning problems with the company's Symbiq infusion pump system. The designation ...

The use of smart pump technology has been proven to reduce the frequency of errors in the administration of intravenous drugs. But software glitches and other potentially dangerous problems persist.

Baxter ($BAX) is facing a new set of regulator entanglements related to the infusion pumps that were yanked from the market two years ago because manufacturing issues ...

Smiths Medical has been urging healthcare providers to update tens of thousands of its hospital syringe pumps after identifying issues with outdated software, and now the FDA is helping to get the ...

Infusion pumps have been plagued with multiple FDA recalls in recent years, and some of the pumps identified in the recalls are still in use, according to a report by DotMed. For example, 200,000 ...

Skin reactions at insulin pump infusion sites are common among people with type 1 diabetes who use the devices and can lead to delivery failure, new research suggests. Insulin pump use is increasingly ...

Pump vs control sites had greater vessel density, fibrosis, fibrinogen, and inflammation including eosinophils, insulin-like-growth factor-1 (IGF-1), and transforming growth factor (TGF) β-3, as well ...